BIOTHERAPY (IMMUNE RESPONSE)

Question 1

Ipilimumab

Answer 1

Monoclonal antibiody to increase antitumor response. For liver, melanoma, metastatic colon/ lung/ renal.
Reactions: enterocolitis, hepatitis, dermatitis, neuropathy.
SE: ab pain, alopecia, anemia, anorexia, constipation, diarrhea, dizziness, cough, edema, inc LFT’s, fatigur, altered potassium, hyper/ hypothyroid, low mg, N/V, wt loss, xerostomia (dry mouth)

Question 2

Nivolumab

Answer 2

Prevents immune response and programs cell death. For colon, H&N, liver, HL, lung, melanoma, renal
Reactions: hypo/ hyperthyroid, hepatitis, nephritis, colitis, pneumonitis, encephalitis (requires high doses of steroids)
SE: abd pain, alopecia, anemia, anorexia, constipation, diarrhea, diziness, edema, inc LFT’s, GI perforation, altered BG/ Ca, low Mg, Nausea, neutropenia, vomiting, wt loss

Question 3

Biotherapy strategies

Answer 3

Includes monoclonal antibodies, protein targeted therapy, angiogenesis inhibitor and cytokines. Can transport radioactive particles and CA vaccines are being studied. Less side effects overall but includes vascular, coagulation, dermatological, immuno, ocular and pulmonary complications.

Question 4

Anti-angiogenesis

Answer 4

Bevacizuman (Avastin), Lenalidomide (Revlimid), Thalidomide

SE: HTN, inc thromboembolic events, proteinuric, hemorrhage, GI perforation, hypothyroid

Question 5

Cytokine

Answer 5

Interleukin-2 (aldosleukin, Interferon a (Roferon)

SE: flu-like symptoms, fatigue, anorexia, myelosuppression, renal/cardio toxicity

Question 6

Protein targeted therapies

Answer 6

Tyrosine kinase inhibitors (Sorafenib, Sunitinib, Imatinib, Erlotinib
MTOR inhib: Temsirolimus, Everolimus
Proteasome inhib: Bortezomib
SE: hand/ food syndrome, rash, cardio tox, N/V/D, low appetite

Question 7

Monoclonal antibody

Answer 7

Targets receptors outside tumor cells to activate a pathway. SE: hand/ food syndrome, N/V/D, fever, chills, fatigue, cardio/ puml tox